PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Magneto-Plasmonic Nanoparticle Grid Biosensor with Enhanced Raman Scattering and Electrochemical Transduction for Development of Nanocarriers for Targeted Delivery of Protected Anticancer Drugs
Version 1
: Received: 15 April 2021 / Approved: 20 April 2021 / Online: 20 April 2021 (17:43:09 CEST)
How to cite:
Ilkhani, H.; Zhong, C.; Hepel, M. Magneto-Plasmonic Nanoparticle Grid Biosensor with Enhanced Raman Scattering and Electrochemical Transduction for Development of Nanocarriers for Targeted Delivery of Protected Anticancer Drugs. Preprints2021, 2021040553. https://doi.org/10.20944/preprints202104.0553.v1
Ilkhani, H.; Zhong, C.; Hepel, M. Magneto-Plasmonic Nanoparticle Grid Biosensor with Enhanced Raman Scattering and Electrochemical Transduction for Development of Nanocarriers for Targeted Delivery of Protected Anticancer Drugs. Preprints 2021, 2021040553. https://doi.org/10.20944/preprints202104.0553.v1
Ilkhani, H.; Zhong, C.; Hepel, M. Magneto-Plasmonic Nanoparticle Grid Biosensor with Enhanced Raman Scattering and Electrochemical Transduction for Development of Nanocarriers for Targeted Delivery of Protected Anticancer Drugs. Preprints2021, 2021040553. https://doi.org/10.20944/preprints202104.0553.v1
APA Style
Ilkhani, H., Zhong, C., & Hepel, M. (2021). Magneto-Plasmonic Nanoparticle Grid Biosensor with Enhanced Raman Scattering and Electrochemical Transduction for Development of Nanocarriers for Targeted Delivery of Protected Anticancer Drugs. Preprints. https://doi.org/10.20944/preprints202104.0553.v1
Chicago/Turabian Style
Ilkhani, H., Chuan-Jian Zhong and Maria Hepel. 2021 "Magneto-Plasmonic Nanoparticle Grid Biosensor with Enhanced Raman Scattering and Electrochemical Transduction for Development of Nanocarriers for Targeted Delivery of Protected Anticancer Drugs" Preprints. https://doi.org/10.20944/preprints202104.0553.v1
Abstract
Safe administration of highly cytotoxic chemotherapeutic drugs is a challenging problem in cancer treatment due to the adverse side effects and collateral damage to non-tumorigenic cells. To mitigate these problems, new promising approaches, based on the paradigm of controlled targeted drug delivery (TDD), utilizing drug nanocarriers with biorecognition ability to selectively target neoplastic cells, are being considered in cancer therapy. Herein, we report on the design and testing of a nanoparticle-grid based biosensing platform to aid in the development of new targeted drug nanocarriers. The proposed sensor grid consists of superparamagnetic gold-coated core-shell Fe2Ni@Au nanoparticles, further functionalized with folic acid targeting ligand, model thiolated chemotherapeutic drug doxorubicin (DOX), and a biocompatibility agent, 3,6,-dioxa-octanethiol (DOOT). The employed dual transduction based on electrochemical and enhanced Raman scattering detection have enabled efficient monitoring of the drug loading onto the nanocarriers, attached to the sensor surface, as well as the drug release under simulated intracellular conditions. The grid’s nanoparticles serve here as the model nanocarriers for new TDD systems under design and optimization. The superparamagnetic properties of the Fe2Ni@Au NPs aid in nanoparticles’ handling and constructing a dense sensor grid with high plasmonic enhancement of the Raman signals due to the minimal interparticle distance.
Keywords
Raman biosensor; Au-coated nanoparticles; hot-spot SERS substrate; anticancer drug nanocarriers; targeted drug delivery sensing; magneto-plasmonic nanoparticles.
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
